Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants

Inclusion Criteria : * Two months old infants on the day of inclusion * Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg * Informed consent form signed by one or both parents or by the guardian and two independent witnesses * Able to attend all scheduled visits and to comply with all trial procedures * Received Bacillus Calmette Guerin (BCG) vaccine between birth and one month of life in agreement with the national immunization calendar. Exclusion Criteria : * Participation in another clinical trial in the four weeks preceding the (first) trial vaccination * Planned participation in another clinical trial during the present trial period * Congenital or acquired immunodeficiency * Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances * Chronic illness at a stage that could interfere with trial conduct or completion * Blood or blood-derived products received since birth * Any vaccination in the four weeks preceding the first trial visit * Any planned vaccination (except BCG, rotavirus, and pneumococcal conjugated vaccines) during the study * Documented history of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b or hepatitis B infection(s) (confirmed either clinically, serologically or microbiologically) * Previous vaccination against hepatitis B, pertussis, tetanus, diphtheria, poliovirus, or Haemophilus influenzae type b infection(s) * Known personal or maternal history of HIV, Hepatitis B (HBsAg) or Hepatitis C seropositivity * Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination * History of seizures * Febrile (rectal equivalent temperature ≥ 38.0°C) or acute illness on the day of inclusion.